A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxal plus a Reduced Dose of Capecitabine vs Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with Taxane
Disease Types
Breast Cancer
Available at
Bethesda, Brandywine, Clinton, Columbia, Rockville, Silver Spring, Wheaton
Contact
Linda Iovanni
MOHRSCH@usoncology.com